New hope for Hard-to-Treat ovarian cancer: drug combo enters human testing
NCT ID NCT06856499
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 3 times
Summary
This early-phase study tests whether combining two drugs, Cirtuvivint and Olaparib, is safe for women with ovarian cancer that no longer responds to platinum chemotherapy. About 50 participants will take the medications on different schedules and visit the clinic regularly for checkups. The goal is to find the best dose and see how well the body tolerates the combination.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIOID OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CU Medicine Clinics
RECRUITINGAurora, Colorado, 80045, United States
-
Universtiy of Colorado Hospital
RECRUITINGAurora, Colorado, 80045, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a custom vaccine train the body to fight ovarian cancer?
- Can a 'Smart Bomb' drug outsmart recurrent ovarian cancer?
- Can a targeted drug boost standard ovarian cancer therapy?
- Can heated chemo during surgery help older women with ovarian cancer?
- Can a daily pill keep BRCA-Linked ovarian cancer at bay?
- New drug cocktail aims to shrink recurrent ovarian tumors